Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer. 2018;118:312-324.
Cancer Progress Timeline: Pancreatic Cancer. American Society of Clinical Oncology (ASCO®) Research & Guidelines website. https://www.asco.org/research-guidelines/cancer-progress-timeline/pancreatic-cancer. Accessed October 6, 2020.
Cappuzzo F, McCleod M, Hussein M, et al. IMpower130: efficacy and safety from a randomised phase 3 study of carboplatin and nab-paclitaxel with or without atezolizumab in 1L advanced non-squamous NSCLC. Presented at: European Society for Medical Oncology (ESMO) Congress; October 19–23, 2018; Munich, Germany. Presentation 2887.
Chabanon RM, Muirhead G, Krastev DB, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest. 2019;129:1211-1228.
Ciriello G, Miller ML, Aksoy BA, et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127-1133.
ClinicalTrials.gov. Olaparib with or without atezolizumab in treating patients with locally advanced unresectable or metastatic non-HER2-positive breast cancer. http://www.clinicaltrials.gov/ct/show/NCT02849496. Accessed September 26, 2020.
ClinicalTrials.gov. A study of atezolizumab in combination with carboplatin or cisplatin + pemetrexed compared with carboplatin or cisplatin + pemetrexed in participants who are chemotherapy-naive and have stage IV non-squamous non-small cell lung cancer (NSCLC) (IMpower 132). http://www.clinicaltrials.gov/ct/show/NCT02657434. Accessed September 30, 2020.
ClinicalTrials.gov. Study of durvalumab+olaparib or durvalumab after treatment with durvalumab and chemotherapy in patients with lung cancer (ORION) (ORION). http://www.clinicaltrials.gov/ct/show/NCT03775486. Accessed September 26, 2020.
ClinicalTrials.gov. Study of olaparib plus pembrolizumab versus chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC) (MK-7339-009/KEYLYNK-009). http://www.clinicaltrials.gov/ct/show/NCT04191135. Accessed September, 2020.
ClinicalTrials.gov. Study of pembrolizumab with maintenance olaparib or maintenance pemetrexed in first-line (1L) metastatic nonsquamous non-small-cell lung cancer (NSCLC) (MK-7339-006, KEYLYNK-006). http://www.clinicaltrials.gov/ct/show/NCT03976323. Accessed September 26, 2020.
Collisson EA, Bailey P, Chang DK, et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207-220.
Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:6411.
Diaz LA, Le D, Maio M, et al. Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies. Presented at: European Society for Medical Oncology (ESMO) Congress; September 27 - October 1, 2019; Barcelona, Spain. Presentation 569.
Ding L, Kim HJ, Wang Q, et al. PARP inhibition elicits STING-dependent antitumor immunity in BRCA1-deficient ovarian cancer. Cell Rep. 2018;25:2972-2980.
Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155-1164.
Fasching PA, Jackisch C, Rhiem K, et al. A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel and carboplatin followed by epirubicin and cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency. Presented at: American Society of Clinical Oncology (ASCO®) Annual Meeting; May 31-June 4, 2019; Chicago, IL. Presentation 506.
FDA approves larotrectinib for solid tumors with NTRK gene fusions [press release]. Silver Springs, MD: US Food and Drug Administration; November 26, 2018. Available at: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions.
FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma [press release]. Silver Springs, MD: US Food and Drug Administration; December 27, 2019. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma.
Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-2092.
Garcia-Campelo R, Arrieta O, Massuti B, et al. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): a randomized phase 2 study GOAL TRIAL (NCT01513174). Poster presented at: American Society of Clinical Oncology (ASCO®) Annual Meeting; June 1-5, 2018; Chicago, IL. Poster 9012.
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020-2031.
Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366-374.
Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23:3711-3720.
Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141-1149.
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763.
Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38:388-394.
Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497-509.
Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 TPS ≥ 1%: open-label, phase 3 KEYNOTE-042 study. Presented at: American Society of Clinical Oncology (ASCO®) Annual Meeting; June 1-5, 2018; Chicago, IL. Presentation LBA4.
Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152-1158.
Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563-580.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-small cell lung cancer. V8.2020. https://www.nccn.org/. Updated September 15, 2020. Accessed September 25, 2020.
Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991.
Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9:722-737.
Papadimitrakopoulou VA, Cobo M, Bordoni R, et al. IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. In: Proceedings from the 19th World Conference on Lung Cancer (WCLC); September 23 -26, 2018; Toronto, Canada. Abstract OA05.07.
Pilie PG, Gay CM, Byers LA, et al. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759-3771.
Postel-Vinay S, Bajrami I, Friboulet L, et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene. 2013;32:5377-5387.
Reck M, Blais N, Juhasz E, et al. Smoking history predicts sensitivity to PARP inhibitor veliparib in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2017;12:1098-1108.
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37:537-546.
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533.
Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375:23-34.
Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202-206.
Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311-319.
Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19:5003-5015.
Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.
Socinski MA, Jotte RM, Cappuzzo F, et al. IMpower150: overall survival analysis of a randomized phase 3 study of atezolizumab + chemotherapy ± bevacizumab vs chemotherapy + bevacizumab in 1L nonsquamous NSCLC. Presented at: American Society of Clinical Oncology (ASCO®) Annual Meeting; June 1-5, 2018; Chicago, IL. Presentation 9002.
Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:2545-2556.
Stewart RA, Pilie PG, Yap TA. Development of PARP and immune-checkpoint inhibitor combinations. Cancer Res. 2018;78:6717-6725.
Teo MY, Seier K, Ostrovnaya I, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36:1685-1694.
Thomas A, Vilimas R, Trindade C, et al. Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study. J Thorac Oncol. 2019;14:1447-1457.
Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570.
Vinayak S, Tolaney SM, Schwartzberg L, et al. Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA: (TOPACIO/Keynote-162). Poster presented at: San Antonio Breast Cancer Symposium®; December 4-8, 2018; San Antonio, TX. Poster PD5-02.
Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.

CME / ABIM MOC

The Rationale for PARP Inhibitors and Their Combination With Immunotherapy in Solid Tumors

Authors: Andrew Tutt, MBChB, PhD, FMedSci; Benjamin Besse, MD, PhD; Alexandra Leary, MD, PhD; Sara M. Tolaney, MD, MPH; Eric Van Cutsem, MD, PhD
CME / ABIM MOC Released: 10/20/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 10/20/2021

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematologists/oncologists and pathologists.

The goal of this activity is to increase knowledge regarding the latest clinical trial data investigating poly (ADP-ribose) polymerase (PARP) inhibitors and their combination with immunotherapy in breast cancer, lung cancer, and pancreatic cancer, as well as to improve confidence in the learners' ability to understand which patients could be eligible for PARP combination therapy.

Upon completion of this activity, participants will:

Increased knowledge regarding the
- Rationale behind the use of PARP inhibitors and their combination with immunotherapy in solid tumors
- Latest clinical trial data investigating PARP inhibitors and their combination with immunotherapy in breast cancer, lung cancer, and pancreatic cancer
Demonstrate greater confidence in their ability to
- Understand which patients could be eligible in the future for treatment with emerging immunotherapy and PARP combinations in patients with breast cancer, lung cancer, and pancreatic cancer

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Andrew Tutt, MBChB, PhD, FMedSci

Director
Breast Cancer Now Toby Robins Research Centre
Institute of Cancer Research and Kings College London
London, United Kingdom

Disclosures

Disclosure: Andrew Tutt, MBChB, PhD, FMedSci, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Artios; AstraZeneca; InBiomation; Merck KGaA; Pfizer; Vertex
Received grants for clinical research from: AstraZeneca; Medivation; Merck KGaA; Myriad Genetics
Owns stock, stock options, or bonds from: InBiomotion

Benjamin Besse, MD, PhD

Head, Cancer Medicine Department
Gustave Roussy Cancer Center
Chair, EORTC Lung Cancer Group
Paris, France

Disclosures

Disclosure: Benjamin Besse, MD, PhD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AbbVie; Amgen; AstraZeneca; BeiGene; Blueprint Medicines; BMS; Boehringer Ingelheim; Celgene; Cristal Therapeutics; Daiichi-Sankyo; Eli Lilly; GSK; Ignyta; IP

Alexandra Leary, MD, PhD

Medical Oncologist
Lead, Gynecology Translational Research Lab
Gustave Roussy Cancer Center
Paris, France

Disclosures

Disclosure: Alexandra Leary, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Clovis; GlaxoSmithKline; MSD; Zentalis
Received grants for clinical research from: Ability; Agenus; AstraZeneca; GSK; Iovance Biotherapeutics; Roche; Sanofi; Tesaro

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancers
Senior Physician
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Disclosures

Disclosure: Sara M. Tolaney, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; AstraZeneca; Athenex; Bristol Myers Squibb; Celldex; Cytomax; Daiichi Sankyo; Eisai; Eli Lilly; Genentech/Roche; G1 Therapeutics; Immunomedics; Kyowa Kirin; Merck; Nanostring; Nektar; Novartis; Odonate; OncoPep; Pfizer; Puma; Samsung Bioepsis Inc; Seattle Genetics
Received grants for clinical research from: AstraZeneca; BMS; Cyclacel; Eisai; Eli Lilly; Exelixis; Genentech/Roche; Immunomedics; Merck; Nanostring; Nektar; Novartis; Odonate; Pfizer; Seattle Genetics

Eric Van Cutsem, MD, PhD

Professor of Internal Medicine
Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium

Disclosures

Disclosure: Eric Van Cutsem, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Array; AstraZeneca; Bayer; Biogen; BMS; Celgene; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; MSD; Novartis; Piere-Fabre; Roche; Servier; Sintes; Taiho
Received grants for clinical research from: Amgen; Bayer; BMS; Boehringer Ingelheim; Celgene; Ipsen; Lilly; Merck KGaA; MSD; Novartis; Roche; Servier

Editors

Amy Furedy, RN, OCN

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Amy Furedy, RN, OCN, has disclosed no relevant financial relationships.

Vandana Iyer, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Vandana Iyer, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

CME / ABIM MOC

The Rationale for PARP Inhibitors and Their Combination With Immunotherapy in Solid Tumors

Authors: Andrew Tutt, MBChB, PhD, FMedSci; Benjamin Besse, MD, PhD; Alexandra Leary, MD, PhD; Sara M. Tolaney, MD, MPH; Eric Van Cutsem, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 10/20/2020

Valid for credit through: 10/20/2021

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

The Rationale for PARP Inhibitors and Their Combination With Immunotherapy in Solid Tumors

Dr Tutt discusses the MOA of PARP inhibitors and immunotherapy and the rationale for their combination in solid tumors.
Andrew Tutt, MBChB, PhD, FMedSci

Emerging PARP Inhibitors and Immunotherapy Combinations in Breast Cancer

Dr Tolaney provides the latest clinical trial data on PARP inhibitors plus immunotherapy in breast cancer.
Sara M. Tolaney, MD, MPH

Looking at the PARP Inhibitors and Immunotherapy Combinations in Pancreatic Cancer

Dr Van Cutsem examines the latest clinical trial data on PARP inhibitors and their combination with immunotherapy in pancreatic cancer.
Eric Van Cutsem, MD, PhD

PARP Inhibitors and Their Combination With Immunotherapy in Lung Cancer

Dr Besse discusses the latest clinical trial data on PARP inhibitors plus immunotherapy in lung cancer.
Benjamin Besse, MD, PhD

Which Adverse Events Can We Expect From PARP Inhibitors and Their Combination With Immunotherapies?

Dr Leary reviews adverse events that can arise from combining PARP inhibitors with immunotherapies.
Alexandra Leary, MD, PhD

Concluding Remarks

Dr Tolaney provides a quick wrap-up of the program.
Sara M. Tolaney, MD, MPH

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers

Page 1 of 9

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Andrew Tutt, MBChB, PhD, FMedSci

Benjamin Besse, MD, PhD

Alexandra Leary, MD, PhD

Sara M. Tolaney, MD, MPH

Eric Van Cutsem, MD, PhD

Editors

Amy Furedy, RN, OCN

Vandana Iyer, PhD

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

CME / ABIM MOC

The Rationale for PARP Inhibitors and Their Combination With Immunotherapy in Solid Tumors

Target Audience and Goal Statement

Disclosures

Faculty

Andrew Tutt, MBChB, PhD, FMedSci

Benjamin Besse, MD, PhD

Alexandra Leary, MD, PhD

Sara M. Tolaney, MD, MPH

Eric Van Cutsem, MD, PhD

Editors

Amy Furedy, RN, OCN

Vandana Iyer, PhD

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Rationale for PARP Inhibitors and Their Combination With Immunotherapy in Solid Tumors

Contents of This CME Activity

The Rationale for PARP Inhibitors and Their Combination With Immunotherapy in Solid Tumors

Emerging PARP Inhibitors and Immunotherapy Combinations in Breast Cancer

Looking at the PARP Inhibitors and Immunotherapy Combinations in Pancreatic Cancer

PARP Inhibitors and Their Combination With Immunotherapy in Lung Cancer

Which Adverse Events Can We Expect From PARP Inhibitors and Their Combination With Immunotherapies?

Concluding Remarks

Educational Impact Challenge